B-cell non-Hodgkin lymphoma

This study tests whether the Gardasil 9 vaccine can help stem cell transplant patients build immunity against HPV. About 48 adults who had a stem cell transplant for blood cancer will receive the vaccine. Researchers will measure antibody levels to see if the vaccine works in the…

This early-phase trial tests whether a vaccine made from a protein called survivin can safely boost the immune system to fight multiple myeloma. The study involves 18 patients who have already responded to initial treatment and are taking lenalidomide as maintenance therapy. The …

This phase II trial tests a vaccine designed to protect stem cell transplant recipients from cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immune systems. The vaccine uses a modified, harmless virus to deliver three CMV proteins, tra…

This study tests a combination of two drugs—venetoclax and vincristine—in people with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior treatment. The goal is to find the safest dose and see if the combo can lead to remission. About 40 adul…

This phase 3 trial compares the usual two-drug therapy (ibrutinib plus obinutuzumab) against a three-drug combo that adds venetoclax in older adults (65+) with untreated chronic lymphocytic leukemia. The goal is to see if the extra drug keeps the cancer away longer and whether pa…

This study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. About 529 people took part. The main goal was t…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This study tests adding vorinostat, a drug that blocks enzymes cancer cells need to grow, to the standard R-CHOP chemotherapy and antibody therapy for people with newly diagnosed advanced diffuse large B-cell lymphoma (DLBCL). The trial has two parts: first, finding the safest do…

This Phase 3 trial compares a new two-drug combination (sonrotoclax plus zanubrutinib) against a standard therapy (venetoclax plus obinutuzumab) in 652 adults with previously untreated chronic lymphocytic leukemia (CLL). The goal is to see which approach better delays disease pro…

This study tests whether adding the drug lenalidomide to standard chemo (R-CHOP) helps people with newly diagnosed, aggressive diffuse large B-cell lymphoma. About 350 patients received either R-CHOP alone or R-CHOP plus lenalidomide. Researchers are tracking how long patients li…

This early-phase trial is testing whether adding the targeted drug zanubrutinib to a standard chemotherapy cocktail (R-PolaCHP) is safe and effective for people with newly diagnosed diffuse large B-cell lymphoma. The study aims to find the best dose and watch for side effects. Ab…

This phase 3 trial is testing whether adding venetoclax to a standard two-drug regimen (ibrutinib and obinutuzumab) helps younger patients with chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. The study involves 720 participants who have not yet …

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…

This study tests whether adding the drug venetoclax to standard chemotherapy can keep high-grade B-cell lymphomas from returning or getting worse. The trial includes 363 people with aggressive lymphoma subtypes. Venetoclax targets a protein that helps cancer cells survive, while …

This study tests an experimental drug called selinexor in adults with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the drug can shrink tumors or control the disease. Participants must have no other proven treatment opt…

This study is for people with a type of slow-growing lymphoma (grades 1-3a) that has returned or not responded to earlier treatment. It tests whether adding other drugs to a standard immunotherapy (obinutuzumab) can improve results. About 73 adults will receive different treatmen…

This study tests whether adding the oral drug selinexor to standard chemotherapy (R-GDP) can help people with relapsed or refractory diffuse large B-cell lymphoma who cannot receive a stem cell transplant or CAR-T therapy. About 500 participants will receive either selinexor at o…

This study tests a two-step treatment for people with relapsed or refractory B-cell Non-Hodgkin lymphoma. First, patients receive a bispecific antibody therapy (Obinutuzumab and Glofitamab) to help the immune system attack cancer cells. Then, they get an infusion of CD19-CAR T ce…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests a new treatment for a rare and aggressive blood cancer called primary plasma cell leukemia. The approach combines chemotherapy, a stem cell transplant, and two infusions of specially engineered immune cells (CAR-T cells) that target the cancer. The goal is to see…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This study is for people with follicular lymphoma, a type of blood cancer, that has come back or no longer responds to treatment. It tests whether adding the drug tazemetostat to standard therapy (lenalidomide plus rituximab) helps keep the cancer from growing longer than the sta…

This trial investigates a new type of immunotherapy called CAR T-cell therapy that targets two proteins, CD19 and CD22, found on B-cell leukemia cells. The therapy is given along with chemotherapy to children and young adults whose leukemia has come back or has not responded to s…

This Phase 3 trial is testing whether a targeted immunotherapy drug called blinatumomab, given alongside low-intensity chemotherapy, works better than standard chemotherapy for older adults (55+) with a specific type of acute lymphoblastic leukemia (ALL). The study involves 303 p…

This early-phase trial is testing whether combining three drugs—tazemetostat, zanubrutinib, and an anti-CD20 antibody (rituximab or obinutuzumab)—is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. The study involves …

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This study tests whether adding the drug ibrutinib to standard chemotherapy before and after a stem cell transplant helps people with a specific type of lymphoma (activated B-cell diffuse large B-cell lymphoma) that has returned or not responded to treatment. About 94 participant…

This early-stage trial is testing a new drug called valemetostat together with two standard drugs (rituximab and lenalidomide) in 60 adults with follicular lymphoma that has come back or not responded to prior treatment. The main goal is to find a safe dose and check for side eff…

This Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab) in 150 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymp…

This phase 2 trial is testing a new drug called zilovertamab vedotin (MK-2140), alone or with another drug nemtabrutinib, in about 189 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to see if the trea…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This early-phase study tests the safety of combining two drugs, moxetumomab pasudotox and rituximab, for people with hairy cell leukemia that has not responded to standard treatment. About 18 adults will receive up to 8 cycles of the drugs through an IV. The main goal is to find …

This phase 3 trial compares a shorter chemotherapy regimen (4 cycles) against the standard 6 cycles, both combined with immunotherapy, for people with newly diagnosed, high-tumor-burden follicular lymphoma. The goal is to see if the shorter treatment is just as effective at keepi…

This early study tests a new drug called ABBV-101 in people with several types of non-Hodgkin lymphoma that have come back or not responded to other treatments. The drug is a pill that targets a protein (BTK) involved in cancer growth. The main goals are to find a safe dose and s…

This early-phase trial is testing an experimental antibody called MEDI-570 in 21 people with certain types of T-cell lymphoma that have come back or not responded to treatment. The goal is to find the safest dose and see how the body handles the drug. MEDI-570 works by targeting …

This early-phase trial is testing whether adding the targeted drug ibrutinib to standard chemotherapy can safely treat HIV-positive patients with a type of lymphoma. The study involves 46 participants and aims to find the best dose and check for side effects. If it works, this co…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This trial was designed to test a milder conditioning regimen using a radioactive antibody (90Y-Epratuzumab) followed by chemotherapy and a stem cell transplant for adults with CD22-positive B-cell acute lymphoblastic leukemia. The goal was to find the safest dose that still cont…

This phase 2 study tests a single infusion of KTE-X19, a CAR T-cell therapy, in 25 Japanese adults whose mantle cell lymphoma or B-cell acute lymphoblastic leukemia has returned or not responded to prior treatments. The goal is to see how well it shrinks tumors and how safe it is…

This early-phase trial is testing a combination of three drugs—rituximab, lenalidomide, and ibrutinib—in people with untreated follicular lymphoma. The goal is to find the safest dose and see how well patients tolerate the mix. The study includes 33 participants with stage II to …

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This Phase 2 trial is testing a combination of three drugs—pirtobrutinib, rituximab, and venetoclax—as a first treatment for people with mantle cell lymphoma who have not had any prior therapy. The goal is to see how many patients achieve a complete response (no cancer detected) …

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This Phase 3 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with a specific, aggressive type of lymphoma (non-GCB DLBCL) live longer without their cancer getting worse. About 611 adults aged 18 to 75 who have not been tre…

This phase II trial tests whether combining three drugs—bendamustine, obinutuzumab, and venetoclax—can improve outcomes for people with untreated mantle cell lymphoma. Bendamustine and venetoclax are chemotherapy drugs that kill or stop cancer cells from growing, while obinutuzum…

This early-phase trial tests whether adding the drug acalabrutinib to CAR T-cell therapy can improve treatment for certain B-cell lymphomas. Acalabrutinib blocks cancer growth pathways, while the CAR T-cells are engineered to attack lymphoma cells. The study involves 23 adults an…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This phase 2 trial tests lenalidomide and rituximab in 120 people with chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this drug combination can control the disease, especially for those who cannot or choose not to have chemotherapy. Participants…

This study tests a new procedure called BEAM (Bariatric Endoscopic Antral Myotomy) to help people with obesity lose weight. The procedure uses a tube down the throat to make small cuts in the stomach muscle, aiming to change how the stomach empties. Twenty adults with a BMI betwe…

This phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This early-phase trial is testing a new drug called venetoclax combined with standard chemotherapy drugs for people with aggressive B-cell lymphoma that has come back or stopped responding to treatment. The main goal is to find the highest safe dose of the new combination. About …

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…

This early-phase study tests a new drug called BGB-11417 (sonrotoclax) in people with B-cell blood cancers that have come back or not responded to treatment. The goal is to find the safest dose and see how well it works alone or combined with other drugs. About 437 adults will ta…

This phase 2 trial compares ibrutinib alone versus ibrutinib plus rituximab in 66 patients with relapsed chronic lymphocytic leukemia (CLL). Ibrutinib blocks cancer growth enzymes, while rituximab helps the immune system attack cancer cells. The study aims to see if the combinati…

This study tests whether adding three targeted antibodies (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy can safely treat people with untreated diffuse large B-cell lymphoma. About 35 adults will receive the antibody combination before and during chemo. The g…

This phase 2 trial is testing a combination of two drugs, acalabrutinib and rituximab, in elderly or frail patients who have not yet been treated for mantle cell lymphoma. The goal is to see how well the drugs shrink or control the cancer. The study involves 48 participants aged …

This study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…

This phase 2 trial tests the drug atezolizumab in 27 people with chondrosarcoma or clear cell sarcoma that cannot be removed by surgery or has spread. Atezolizumab is an immunotherapy that helps the body's immune system attack cancer cells. The main goal is to see if the drug can…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study tests whether adding the targeted drug copanlisib to two immunotherapy drugs (nivolumab and ipilimumab) can better control advanced solid tumors that have changes in the PIK3CA or PTEN genes. About 54 adults with cancers that have spread or cannot be removed will recei…

This study tests three different chemotherapy combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see if adding a targeted drug called acalabrutinib to standard chemo improves how well the cancer responds. Ar…

This phase 2 trial tests the drug ibrutinib in 44 people with hairy cell leukemia that has come back after treatment. Ibrutinib works by blocking a protein that helps cancer cells grow. The main goal is to see how many patients achieve remission within 32 weeks.

This phase 3 trial tests whether adding nivolumab to standard chemo-immunotherapy improves outcomes for people with newly diagnosed primary mediastinal B-cell lymphoma. About 244 participants will receive either the combination or standard therapy alone. The main goal is to see i…

This early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The goal is to find the safest dose and see if the combination works better than standard treat…

This early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…

This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …

This large phase 3 study tests whether adding the drug blinatumomab to standard chemotherapy can improve outcomes for children and young adults with newly diagnosed B-cell acute lymphoblastic leukemia or lymphoma, including those with Down syndrome. The trial enrolls over 6,700 p…

This study tests whether a stem cell transplant followed by the drug rituximab works better than rituximab alone for people with mantle cell lymphoma whose cancer is in first complete remission. About 689 adults aged 18 to 70 are taking part. The goal is to see which approach hel…

This early-stage trial is testing a new drug called AZD0486 in about 226 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and follicular lymphoma. The drug is a bispecific antibody designed to help the body's immune T-cells recognize and…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This trial explores whether adding the drug tazemetostat (Tazverik) to standard CAR T cell therapy can help the immune cells better recognize and destroy lymphoma cells. It enrolls people with diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma who have al…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This early-phase study tests the safety of the immunotherapy drug atezolizumab given after a patient's own immune cells have been modified and infused back (adoptive cell transfer). It includes 40 adults with advanced blood or solid cancers that no longer respond to standard trea…

This phase II trial tests a personalized cell therapy called tisagenlecleucel (Kymriah) in children and young adults with high-risk B-cell acute lymphoblastic leukemia who still have detectable cancer cells after initial chemotherapy. The treatment involves collecting the patient…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This phase II trial is studying a combination of chemotherapy (Hyper-CVAD) and the targeted drug dasatinib, with or without a donor stem cell transplant, in 97 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see how well this approa…

This study tests two drugs, mosunetuzumab and lenalidomide, together in people with follicular lymphoma, a type of blood cancer. It includes 237 participants and compares giving one drug as a shot under the skin versus through an IV. The goal is to see if the combination is safe …

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This Phase 3 trial compares the drug acalabrutinib to a combination of chlorambucil and rituximab in people with previously untreated chronic lymphocytic leukemia (CLL). The study includes 155 participants and measures how long the cancer stays under control (progression-free sur…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…

This study is testing a combination of three drugs—obinutuzumab, ibrutinib, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the best dose and see how well the combination …

This phase II trial tests a two-step approach for people with relapsed or refractory large B-cell lymphoma who are eligible for a stem cell transplant. First, patients receive tafasitamab (an antibody) plus lenalidomide, followed by tafasitamab combined with ICE chemotherapy. The…

This phase 2 study tests acalabrutinib, a targeted drug, in 107 people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see how well the drug shrinks tumors and controls the disease. Participants either had prior treatment or are new to therapy and cannot t…

This early-phase trial tests the safety of giving patients modified immune cells from a donor to fight B-cell leukemia or lymphoma that has come back after a stem cell or organ transplant. The cells are designed to target a protein called CD19 on cancer cells. Only 19 patients ar…

This study tests a combination of two drugs, avelumab and M6620, in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see if the combination can help contro…

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This early-phase trial tests a new type of CAR-T cell therapy for people with relapsed or hard-to-treat acute lymphoblastic leukemia. The cells are engineered to recognize and kill leukemia cells, but also include a safety switch that can be turned on to calm them down if side ef…

This study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation (hypofractionated) in people with advanced solid tumors or liver/bile duct cancers that have spread. The goal is to find the safest dose and see if the combination can shrink tu…

This phase II trial tests whether adding the targeted drug acalabrutinib to standard R-CHOP chemotherapy improves outcomes for people with untreated mantle cell lymphoma. About 105 participants will receive the combination, then some will proceed to stem cell transplant. The stud…

This study tests whether giving two drugs—acalabrutinib and obinutuzumab—in cycles can control chronic lymphocytic leukemia (CLL) and allow patients to stop treatment for periods of time. About 60 adults with untreated CLL who need therapy will receive the combination. The goal i…

This phase 2 trial tests whether a combination of two oral drugs, encorafenib and binimetinib, works better than the current drug vemurafenib for people with hairy cell leukemia that has a BRAF mutation and has either not responded to treatment or returned. About 28 adults will t…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This study tests a two-drug combination (ibrutinib and rituximab) in people with mantle cell lymphoma that has returned or not responded to treatment, or in older adults newly diagnosed. The goal is to shrink or control the cancer. About 113 participants will receive the drugs to…

This early-phase trial is testing a combination of the immunotherapy drug atezolizumab, two chemotherapy drugs (gemcitabine and oxaliplatin), and the targeted antibody rituximab in 24 patients with transformed diffuse large B-cell lymphoma that has come back or stopped responding…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study tested a two-step drug combination for people newly diagnosed with mantle cell lymphoma, a type of blood cancer that is not curable with standard treatments. Twenty-three patients who were eligible for a stem cell transplant received rituximab and bendamustine followed…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…

This study tests a drug called MT-2111 (loncastuximab tesirine) in people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The trial has two parts: first, to find a safe dose, and second…

This early-phase trial tests the safety of giving patients their own genetically modified T-cells to fight relapsed B-cell acute lymphoblastic leukemia. The study includes children and young adults up to age 26 whose leukemia has returned or is hard to treat. The modified T-cells…

This phase 3 study tests whether a combination of two targeted drugs, ibrutinib and venetoclax, works better than the current standard therapy (chlorambucil plus obinutuzumab) for adults with chronic lymphocytic leukemia (CLL) who have not yet been treated. The main goal is to se…

This early-phase study tests whether drinking milk from genetically engineered goats (which produce a human enzyme found in breast milk) can reduce the risk of graft versus host disease—a serious immune reaction—in blood cancer patients receiving a donor stem cell transplant. Abo…

This early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…

This early-phase study tests a new drug (JNJ-87801493) combined with immune-activating therapies (T-cell engagers) in about 70 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to other treatments. The main goals are to check safety and find the best dos…

This early-phase trial is testing a new treatment called JNJ-90009530, a type of CAR-T cell therapy that targets a protein called CD20 on lymphoma cells. The study includes 21 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have already tried other treatments. …

This early-phase trial tests whether a child's own immune cells, genetically modified to recognize and attack leukemia cells, are safe and can be given in the right dose. Six children and young adults with CD19-positive acute lymphoblastic leukemia that has returned after treatme…

This early-stage study tests a new oral drug, JNJ-88998377, in about 58 people with relapsed or refractory B-cell non-Hodgkin's lymphoma (a type of blood cancer). The main goals are to check the drug's safety and find the best dose for future studies. Participants must have measu…

This phase 2 trial is testing a combination of three drugs—tafasitamab, lenalidomide, and rituximab—in people aged 80 and older with untreated diffuse large B-cell lymphoma (DLBCL). The goal is to see if this gentler, chemotherapy-free regimen can shrink or eliminate tumors after…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This study tests whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely stop taking acalabrutinib and obinutuzumab once their cancer responds very well, instead of continuing treatment indefinitely. The goal is to reduce serious side…

This study tests a new treatment called rapcabtagene autoleucel, a type of CAR-T cell therapy, in adults with certain blood cancers like chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Some participants also receive the drug ibrutinib. The goal is to…

This early-phase study tests a new treatment for patients with relapsed or hard-to-treat lymphoma in the brain or spinal cord. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells. The main goals are to check safety and see if the treatme…

This study tests a treatment using a patient's own immune cells, modified to find and attack cancer cells that carry a marker called CD19. It is for people with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back. The goal is to see …

This early-phase trial tests a new treatment for people with a rare and hard-to-treat type of lymphoma that has spread to the brain or spinal cord. The therapy uses the patient's own immune cells, modified to target two markers (CD19 and CD22) on cancer cells, and is given throug…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This early-phase study tests a new drug called JNJ-80948543 in people with non-Hodgkin lymphoma or chronic lymphocytic leukemia whose cancer has returned or not responded to other treatments. The drug works by redirecting the body's T-cells to attack cancer cells. The main goals …

This pilot study tests whether giving special immune cells called T-APCs after CAR T cell therapy can help the CAR T cells persist longer in the body and prevent leukemia from returning. It involves 30 children and young adults with relapsed or refractory CD19+ leukemia who have …

This early-phase trial tests two experimental drugs, JNJ-80948543 and JNJ-75348780, given together to people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study involves 19 participants and aims to find the safest dose and check for side effects. It is not yet know…

This Phase 1 trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. Patients' own immune cells are collected, genetically modified to recognize and attack cancer cells, and then infused back af…

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This phase II trial tests whether ultra low dose radiation, given before or after chemotherapy-free targeted therapy, can help control mantle cell lymphoma that has returned or stopped responding to treatment. About 51 adults with measurable disease will receive the radiation, an…

This phase 2 trial tests four different drug combinations in 373 patients aged 60 and older with untreated mantle cell lymphoma. The goal is to see which combination best delays cancer progression. Patients receive rituximab plus bendamustine, with or without bortezomib, followed…

This phase 3 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) helps people with untreated mantle cell lymphoma live longer without their cancer getting worse. About 635 patients aged 65 and older are taking part. The…

This early-stage study tests a mix of six drugs (called ViPOR-P) in adults with B-cell lymphomas that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 34 participants will take pills and receive infusions o…

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and rituximab—in 108 people with untreated mantle cell lymphoma. The goal is to see if the treatment can make the cancer undetectable in the blood (MRD-negative) after about a year. Those who achieve…

This study tests an experimental antibody called epcoritamab, which helps the immune system target and kill cancer cells. It is being tested alone or with other drugs in about 194 people with relapsed/refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. The goal i…

This study compares a targeted immune therapy called blinatumomab to standard chemotherapy in 669 children and young adults (ages 1-30) whose B-cell acute lymphoblastic leukemia has returned after initial treatment. The goal is to see if blinatumomab can keep the cancer away long…

This study tests a drug called epcoritamab, alone or with other treatments, in people with B-cell non-Hodgkin lymphoma, a type of blood cancer. The goal is to find the best dose and see how well it works. About 543 participants will receive the drug under the skin or through an I…

This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…

This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma. The study includes 320 participants and aims to see if the drug can shrink tumors or delay cancer growth. Researchers are also checking for…

This early-stage study tests an experimental drug called RO7567132, alone or with another drug (atezolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shr…

This early-phase study tests whether adding mosunetuzumab after a stem cell transplant is safe for people with aggressive B cell lymphoma that has come back or not responded to prior treatments. Mosunetuzumab is an engineered antibody that helps the body's T cells recognize and k…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study aimed to test a new CAR-T cell therapy that targets a protein called Igβ on cancer cells in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The trial planned to enroll patients who had already tried at least two other treatments. However, the study …

This study tests a drug called blinatumomab given after a stem cell transplant to help prevent relapse in people with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma. About 44 participants will receive the drug as maintenance therapy. The goal is to see if it i…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This study tests a new treatment for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior therapy. The treatment combines two drugs (tafasitamab and lenalidomide) with standard chemotherapy, followed by a stem cell t…

This study tests whether adding the targeted drug ibrutinib to standard chemotherapy (R-CHOP) helps people with a hard-to-treat type of lymphoma called ABC-DLBCL. About 75 adults aged 18-65 with a poor prognosis will receive the combo for 6 cycles, then take ibrutinib alone for 1…

This study tests whether adding sonrotoclax to the standard drug zanubrutinib works better than zanubrutinib alone for adults with untreated chronic lymphocytic leukemia (CLL). About 94 participants will receive either the combination or the single drug. The goal is to see if the…

This phase 2 trial tests a new treatment plan for teenagers and adults with B-cell acute lymphoblastic leukemia. Patients receive immunotherapy before a stem cell transplant using their own cells, followed by a CD22/CD19 CAR-T 'sandwich' to reduce the risk of relapse. The study a…

This early-stage study tested a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in 28 adults with a severe form of B-cell leukemia that had returned or not responded to prior treatments. The main goal was to find safe doses and identify side eff…

This study tests a new drug called englumafusp alfa, which helps the immune system attack cancer cells. It is given together with either obinutuzumab or glofitamab to people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. The trial has three par…

This study was designed to test a new cell therapy called B7H3 CAR-T for people with advanced solid tumors that have a specific marker (B7H3). The goal was to see if the treatment is safe and shrinks tumors. However, the study was withdrawn before enrolling any participants, so n…

This early-phase study tests whether giving a patient's own genetically modified immune cells (CAR T-cells) after high-dose chemotherapy and a stem cell transplant is safe for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Seve…

This study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …

This phase II trial tests the drug palbociclib in 43 patients with advanced cancers that have extra copies of the CDK4 or CDK6 genes. The drug works by blocking signals that tell cancer cells to multiply. Researchers will measure how many patients' tumors shrink or stop growing f…

This phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…

This phase II trial tests the drug crizotinib in 20 adults with advanced or hard-to-treat cancers that have a specific genetic change called MET exon 14 deletion. Crizotinib is a pill that blocks signals cancer cells need to grow. The study aims to see if the drug can shrink tumo…

This study tests a subcutaneous (under the skin) injection of blinatumomab for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or minimal residual disease. The goal is to see if this new method is safe and effective. About 181 adults and adolescents…

This phase II trial tests a drug called copanlisib in 35 patients with advanced cancers that have a specific mutation in the PTEN gene. The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or slow the disease. The study is small …

This study tests two oral drugs, pirtobrutinib and venetoclax, in 46 people with Waldenström macroglobulinemia who have already had at least one prior treatment. The goal is to see if the combination can shrink the cancer and improve response rates. Researchers are also tracking …

This study tests a new treatment plan for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a donor stem cell transplant. The approach uses a 'sandwich' strategy: first, patients receive two types of CAR T-cells (targeting CD22 and CD19), th…

This early-phase trial is testing whether adding the drug venetoclax to a chemotherapy regimen originally designed for children can be safe and effective for adults aged 18-54 with a specific, aggressive form of B-cell acute lymphoblastic leukemia (Ph-like ALL). The study will en…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This study was designed to test a new treatment called BAFFR CAR-T for people with B-cell blood cancers that came back or didn't respond to other treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. However, the trial was withdrawn before en…

This Phase III trial is testing whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a newly diagnosed type of acute lymphoblastic leukemia (ALL) live longer and stay cancer-free longer. About 488 participants are randomly assigned to rece…

This early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…

This phase II trial tests a drug called GSK2636771 in 24 patients whose advanced cancers have a PTEN mutation or deletion. The drug blocks a protein (PI3K-beta) that may help these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from growing.

This phase II trial tests a drug called GSK2636771 in 35 patients whose cancers have lost a protein called PTEN. The drug blocks a growth signal that these cancers may rely on. Researchers hope to see if it can shrink tumors or stop them from growing.

This early-phase trial tests a new drug called BI 765179, an antibody that helps the immune system fight cancer. It is given alone or with other drugs (ezabenlimab or pembrolizumab) to adults with advanced solid tumors or head and neck cancer. The study aims to find the best dose…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This phase 3 trial tests whether acalabrutinib is as effective as ibrutinib for people with high-risk chronic lymphocytic leukemia (CLL) who have already tried other treatments. About 533 participants will receive either acalabrutinib or ibrutinib pills. The main goal is to see h…

This early-stage study tested a combination of two drugs (pembrolizumab and pralatrexate) in 13 people with peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find the safest dose and see if the combo could shrink tumors. The approac…

This phase 2 trial tests whether combining lenalidomide (a drug that cuts off blood supply to cancer and boosts immunity) with a vaccine can help people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have high-risk genetic features. Th…

This early-phase trial tests the safety and best dose of combining ibrutinib and palbociclib in 28 patients with mantle cell lymphoma that has come back after treatment. Both drugs block enzymes that help cancer cells grow. The study aims to find a dose that is safe enough to tes…

This study tests whether the antiviral drug entecavir can prevent hepatitis B from reactivating in people with a type of blood cancer (CD20-positive B-cell lymphoma) who have had hepatitis B in the past but cleared it. The 84 participants will take entecavir before starting their…

This study tests a combination of targeted therapy (ibrutinib) and immunotherapy (rituximab) followed by strong chemotherapy in young patients with newly diagnosed mantle cell lymphoma, an aggressive blood cancer. The goal is to see if this approach improves response rates while …

This early-phase study tests a new way to treat advanced solid tumors by combining low-dose radiation with a drug called 5-aminolevulinic acid (ALA). The drug is thought to make cancer cells more sensitive to radiation, allowing lower doses to be used and potentially reducing har…

This phase 3 trial compares a new immunotherapy called epcoritamab (given as a shot under the skin) to standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 483 participants will be randomly assigned to re…

This early-phase trial tests a new drug called ACY-1215 (ricolinostat) combined with either ibrutinib or idelalisib in people whose chronic lymphocytic leukemia has returned after prior treatment. The main goal is to find a safe dose, while also checking if the combination helps …

This study tests whether a less invasive heart valve replacement (TAVR) is safe and effective for people with moderate aortic stenosis, a condition where the heart's aortic valve is partially blocked. About 650 participants will receive the TAVR device and be monitored for compli…

This study tests a new treatment called SJCAR19 for children and young adults up to age 21 whose B-cell acute lymphoblastic leukemia (ALL) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are collected, modified in a lab…

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This early-phase trial is testing a two-step approach for people with newly diagnosed, high-risk mantle cell lymphoma. First, patients receive a combination of acalabrutinib (a targeted drug) and rituximab (an antibody). Then, they get a one-time infusion of their own genetically…

This study tests two different drug combinations in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 600 participants will receive either acalabrutinib plus venetoclax or venetoclax plus obinutuzumab. The goal is to see which com…

This phase 2 trial tests whether adding venetoclax to ibrutinib and an anti-CD20 antibody can better clear minimal residual disease in people with newly diagnosed mantle cell lymphoma. About 210 patients will receive either the two-drug or three-drug combo for up to two years, pl…

This early-phase trial is testing a combination of two immunotherapy drugs—pembrolizumab and recombinant interleukin-12—in 36 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can help …

This study tests a drug called blinatumomab, given as a shot under the skin, combined with low-intensity chemotherapy for people aged 60 and older (or younger adults who are not healthy enough for strong chemo) with B-cell acute lymphoblastic leukemia. The goal is to see if this …

This phase II trial is testing a combination of targeted drugs (ibrutinib, rituximab, venetoclax) plus chemotherapy in 51 newly diagnosed young adults with mantle cell lymphoma. The goal is to see if this approach can achieve a complete response—meaning no signs of cancer—after t…

This phase II trial tests a combination of three drugs—acalabrutinib, lenalidomide, and rituximab—in 60 people with untreated follicular lymphoma that has spread. The goal is to see if this chemo-free mix can make the cancer disappear completely. Participants take the drugs by mo…

This study tests a combination of two drugs, acalabrutinib and rituximab, in people aged 65 and older with newly diagnosed mantle cell lymphoma who haven't had treatment yet. Acalabrutinib blocks enzymes that help cancer grow, while rituximab targets and kills cancer cells. The g…

This study tests a drug called loncastuximab tesirine in 21 people with Waldenström macroglobulinemia, a rare blood cancer, whose disease has not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and lower abnormal protein levels. Partic…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This phase 2 trial tests a new COVID-19 booster vaccine (GEO-CM04S1) in 80 people with chronic lymphocytic leukemia (CLL). The goal is to see if this vaccine triggers a stronger immune response than standard mRNA boosters. Participants will receive either the new vaccine or a sta…

This study tests a drug called ACP-196 (acalabrutinib) in 124 adults with mantle cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. This is an open-label, phase 2 trial, meaning every…

This early-phase trial tests a new cell therapy called ANCHOR for people with B-cell lymphoma or leukemia that has returned or not responded to treatment. The therapy uses immune cells from a healthy donor that are engineered to recognize and attack cancer cells carrying the CD19…

This early-phase study tests whether adding the drug azeliragon to radiation therapy is safe for people whose cancer has spread to the lining of the brain and spinal cord. About 21 adults with solid tumors or aggressive brain cancers will receive the combination. The main goal is…

This early-phase trial tests a gene therapy approach for people with HIV who also have lymphoma that has returned or not responded to treatment. Researchers take the patient's own stem cells, add anti-HIV genes in the lab, and return them after a stem cell transplant. The goal is…

This study tests the safety and effectiveness of tafasitamab, given alone or with other drugs (lenalidomide, parsaclisib, or R-CHOP), in about 72 Japanese adults with Non-Hodgkin lymphoma. The goal is to find the best doses and see if the treatment shrinks tumors. Participants ha…

This study tests whether a new drug combination (zanubrutinib plus rituximab) works better than standard chemotherapy (bendamustine plus rituximab) for people with untreated mantle cell lymphoma who cannot have a stem cell transplant. About 510 participants will be randomly assig…

This study tests a new drug called pirtobrutinib against other approved drugs for mantle cell lymphoma, a type of blood cancer. About 500 people who have already had at least one prior treatment will take part. The goal is to see if the new drug works better at controlling the di…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…

This early-phase study tests a new biologic drug called PIT565 in 61 adults with B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment. The main goals are to check the drug's safety, find the best dose, and see ho…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This phase II trial tests whether radiation therapy can help control cancer that has spread or grown after immunotherapy. About 230 patients with metastatic or lymphoid cancers will receive targeted radiation to see if it stabilizes the disease or shrinks tumors. The study also m…

This study tests a combination of three drugs (obinutuzumab, zanubrutinib, and lenalidomide) followed by a short course of chemotherapy (cytarabine) in 39 adults newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal is to see if this approach can shrink or elim…

This study tests a subcutaneous (under the skin) injection of blinatumomab in children under 12 with relapsed/refractory or minimal residual disease positive B-cell acute lymphoblastic leukemia. The goal is to see if this easier-to-give form is safe and effective at achieving rem…

This study tests whether adding the immunotherapy drug pembrolizumab to standard R-ICE chemotherapy can help people with diffuse large B-cell lymphoma that has returned or not responded to earlier treatment. About 65 adults will take part. The main goal is to see how many are ali…

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…

This study tests whether combining zanubrutinib (a BTK inhibitor) with rituximab (an antibody) can help control chronic lymphocytic leukemia or small lymphocytic lymphoma in people who have not had treatment before. About 60 participants will receive the combination, and research…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…

This study tests a drug called ulixertinib in people with advanced cancers that have specific changes in the BRAF gene (fusions or non-V600 mutations). The drug blocks signals that tell cancer cells to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that ha…

This study tests a drug called MLN0128 (TAK-228) in 49 adults with advanced cancers that have TSC1 or TSC2 mutations. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if tumors shrink or stop growing, and track how long patients live or stay …

This early-phase trial is testing a combination of two drugs, ibrutinib and lenalidomide, in people with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and understand side effects. About 39 participants with d…

This study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…

This early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Resea…

This early-phase trial is testing a combination of three drugs—lenalidomide, ibrutinib, and rituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. The main goal is to find the safest …

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study offers ongoing treatment with the drug CC-122 (Avadomide) to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor long-term safety and serious side effects. Par…

This early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…

This Phase 2 trial tests whether adding carfilzomib to ibrutinib improves outcomes for people with Waldenström's macroglobulinemia, a rare blood cancer. About 99 participants will receive either the combination or ibrutinib alone. The goal is to see if the combo leads to higher r…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This phase 2 trial tests whether adding the targeted antibody tafasitamab to a standard chemotherapy regimen (DA-EPOCH, with or without rituximab) can improve outcomes for adults newly diagnosed with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL). Th…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This study tests a combination of two targeted drugs, ibrutinib and venetoclax, in 45 adults with a rare blood cancer called Waldenström macroglobulinemia who have a specific gene mutation (MYD88). The goal is to see if the combo can shrink the cancer significantly. Participants …

This phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This phase 3 trial compares the targeted drug acalabrutinib against two standard combination therapies (idelalisib plus rituximab or bendamustine plus rituximab) in 310 adults with chronic lymphocytic leukemia (CLL) that has returned or not responded to prior treatment. The main …

This study tests an experimental drug, odronextamab, in people with aggressive B-cell non-Hodgkin lymphoma that has come back or no longer responds to treatment. About 216 participants will receive either the new drug or standard therapy to compare safety, effectiveness, and qual…

This early-phase trial tests a universal (donor-derived) CAR-T cell therapy called UWD-19 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. Up to 30 participants will receive a single infusion of these cells after chemotherapy, along wi…

This study tests an experimental drug called KL590586, taken as a capsule, in people with advanced solid tumors that have specific RET gene changes. The trial has two phases: Phase I checks safety and the right dose, while Phase II looks at how well the drug shrinks tumors. Up to…

This phase 3 study tests whether a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) works better than a standard chemotherapy regimen for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. About 208 adu…

This phase II trial is testing the drug binimetinib in 53 people whose cancers (excluding melanoma) have a specific genetic change called an NRAS mutation. Binimetinib blocks certain proteins that help these cancer cells grow. The study aims to see if the drug can shrink tumors o…

This study tests a combination of two drugs, tafasitamab and zanubrutinib, in people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combination works better than either drug alone to control the cancer. About…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This early-stage study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses specially engineered immune cells from a healthy donor to attack cancer cells. T…

This study looks at whether it is safe to remove one immune-suppressing drug, mycophenolate mofetil (MMF), from the standard treatment plan after a stem cell transplant for blood cancers. Sixty adults aged 18 to 75 will receive the transplant without MMF and be monitored for up t…

This phase 2 trial tests the drug crizotinib in patients with advanced cancers (other than lung cancer) that have a specific genetic change called ALK rearrangement. Crizotinib works by blocking the ALK protein, which may stop cancer cells from growing. The study enrolled only 5 …

This phase II trial tests the drug trametinib in 35 patients with advanced cancers that have certain BRAF mutations or fusions. The goal is to see if trametinib can shrink or stop cancer growth by blocking proteins that help cancer cells grow. The study focuses on patients whose …

This study tests a drug called ado-trastuzumab emtansine in people whose cancers have too many HER2 receptors (HER2 amplification), but not breast or stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Researchers want …

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This phase II trial tests whether combining pembrolizumab (Keytruda) and tazemetostat can help prevent aggressive B-cell lymphoma from returning after patients have already received a stem cell transplant or CAR-T cell therapy. The study enrolls 32 adults and will measure how lon…

This phase II trial is testing the drug defactinib in 35 patients whose advanced cancers have a specific genetic change called an NF2 mutation. The drug works by blocking a protein that may help these cancer cells grow. Researchers want to see if defactinib can shrink tumors or s…

This study tests a new treatment for adults with a specific type of leukemia (Philadelphia chromosome-positive B-ALL). The treatment uses a patient's own immune cells that are modified in a lab to find and attack cancer cells. The goal is to see if this approach is safe and can h…

This study is for people aged 65 and older who have chronic lymphocytic leukemia (CLL) that hasn't been treated yet. It compares three treatment plans: a standard chemo-immunotherapy (bendamustine plus rituximab), a targeted therapy plus immunotherapy (ibrutinib plus rituximab), …

This phase 2 trial tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have a blood condition called autoimmune hemolytic anemia (AIHA) that has come back or not responded to treatment. The study aims to see if acalabrutinib can control the ane…

This Phase 3 study tests whether a new combination of drugs (mosunetuzumab plus lenalidomide) works better than the current standard (rituximab plus lenalidomide) for people with follicular lymphoma that has returned after at least one prior treatment. About 478 participants will…

This study tests a drug called AZD1775 in people whose advanced cancers have a BRCA1 or BRCA2 gene mutation. The drug blocks a protein (WEE1) that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with various adva…

This study tests a new chemotherapy-free treatment for marginal zone lymphoma, a slow-growing blood cancer. It combines two drugs, Copanlisib and Rituximab, to see if they can control the disease better than Rituximab alone, while avoiding harsh chemo side effects. The trial incl…

This phase 2 trial tests obinutuzumab, a targeted antibody, in 56 people with newly diagnosed marginal zone lymphoma who need treatment but cannot have or have failed local therapy. The goal is to see if this drug can shrink tumors without the side effects of chemotherapy. Partic…

This study tests a new treatment for people with high-risk B-cell non-Hodgkin lymphoma that has come back. After a stem cell transplant, patients receive genetically modified immune cells designed to recognize and attack cancer cells. The goal is to see if this approach is safe a…

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This study tests whether combining two drugs, epcoritamab and lenalidomide, can shrink or eliminate tumors in people with untreated follicular lymphoma, a slow-growing blood cancer that is not currently curable. About 29 adults with stage 1-3a disease who need treatment will rece…

This phase II trial is testing whether adding the drug asciminib to standard treatment can improve outcomes for people newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 55 participants and involves several phases o…

This early-stage trial tests an experimental oral drug called ABBV-525 in people with B-cell blood cancers like lymphoma and leukemia. The study aims to find a safe dose and check for side effects. About 78 adults will take the drug in different dose groups over up to 64 months.

This study tests a device that delivers specific light and sound patterns to the brain, aiming to slow the progression of mild-to-moderate Alzheimer's disease. About 670 participants will use the device at home for an hour daily over a year, with half receiving a sham (inactive) …

This study aimed to test a new CAR-T cell therapy that targets three proteins (CD20, CD19, and CD22) on cancer cells in people with B-cell lymphoma that returned or didn't respond to treatment. The therapy was designed to help the immune system attack the cancer. However, the tri…

This phase 2 trial tests capivasertib (AZD5363) in 35 patients with advanced cancers that have an AKT mutation. The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing.

This study tests a new oral drug called acalabrutinib (ACP-196) in people with chronic lymphocytic leukemia (CLL) or related blood cancers that have not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink or control the cancer. About …

This study tests a drug called copanlisib in people whose cancers have a specific genetic mutation (PIK3CA). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with advanced…

This study tests a combination of two drugs, tafasitamab and lenalidomide, in adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatments. Participants have had 1 to 3 previous therapies but cannot receive high-dose chemo or a stem cell trans…

This early-phase trial tests a new treatment for people with B-cell cancers (like leukemia or lymphoma) that haven't improved with standard therapies. The approach uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main…

This study tests a new, fast-made CAR-T cell therapy (UF-KURE19) for people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose in 21 adults. Researchers also look at how well the therapy shri…

This study tests a new drug called epcoritamab (given as a shot under the skin) against standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 72 participants in China will be randomly assigned to get eithe…

This phase II trial tests the drug taselisib in 70 patients with advanced cancers (excluding breast cancer) that have a specific genetic change called a PIK3CA mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if taselisib can sh…

This study tests whether giving a mix of targeted drugs (rituximab, lenalidomide, acalabrutinib, tafasitamab) before and with standard chemotherapy can better control a fast-growing type of lymphoma called DLBCL. About 62 adults with newly diagnosed disease will participate. The …

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This phase 3 trial tests imatinib, a targeted cancer drug, with two different chemotherapy backbones in children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if a less intense chemo regimen works as well as the s…

This early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when com…

This study tests whether giving the immunotherapy drug pembrolizumab before standard surgery can shrink tumors in people with a specific type of uterine cancer (MMRd). Twelve participants will receive 9 cycles of pembrolizumab before their hysterectomy. The goal is to see how man…

This study tests a new way to do stem cell transplants for children and young adults (up to age 22) with blood cancers like leukemia. Doctors remove certain immune cells from donated stem cells to lower the risk of graft-versus-host disease, a serious complication. The goal is to…

This early-stage trial is testing an experimental oral drug called APG-2575 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to check the drug's safety and find the best dose. About 74 participants will take…

This study tests whether a once-weekly medication (efanesoctocog alfa) can improve or prevent joint damage in 37 people with moderate or severe hemophilia A. Participants receive the drug for 12 months, and doctors use ultrasound and MRI to check joint health. The goal is to see …

This phase 2 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (R-CHOP) improves outcomes for people with untreated diffuse large B-cell lymphoma (DLBCL). About 450 participants will receive one cycle of R-CHOP, then two-thirds will get five more…

This study tests a new drug called glofitamab, given alone or with obinutuzumab, in people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior treatments. The trial has three parts to find the best dose and check safety and effectiveness. About 940 par…

This study tested a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal was to see how many patients had their tumors shrink or di…

This study tests whether transferring stool from a healthy person into the gut of adults with blood cancers can restore good bacteria lost during chemotherapy. The goal is to reduce dangerous infections and improve quality of life. One hundred participants will be followed long-t…

This study tests whether adding the targeted drug rituximab to standard chemotherapy can improve outcomes for children and teens with aggressive B-cell lymphoma or leukemia. About 650 participants from Europe will receive different treatment schedules to find the best balance of …

This early-stage study tests an oral drug called MK-1026 in 12 Chinese adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to prior therapies. The main goals are to check the drug's safety and how the body processes it. Researchers will also look…

This phase 3 trial compares three treatment approaches for people with previously untreated chronic lymphocytic leukemia (CLL): continuous ibrutinib alone, a fixed-duration combination of venetoclax plus obinutuzumab, or a fixed-duration combination of ibrutinib plus venetoclax. …

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This early-phase study tests a new two-drug combination (pevonedistat and ibrutinib) in adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effec…

This phase II trial tests a new biologic drug called ZG005 in 50 adults with advanced solid tumors that have not responded to or are not suitable for standard treatments. Participants receive ZG005 by IV every three weeks. The study measures how many tumors shrink and tracks side…

This study tests whether a new drug combination (loncastuximab tesirine plus rituximab) works better than standard chemotherapy for adults with diffuse large B-cell lymphoma that has returned or not improved after initial treatment. About 440 participants will be randomly assigne…

This early-stage study tests a new approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatment. Researchers take a patient's own T cells, modify them in the lab to recognize and attack leukemia cells, and infuse th…

This phase II study tests a daily pill called PCI-32765 (ibrutinib) in 86 people with chronic lymphocytic leukemia or small lymphocytic lymphoma who are over 65 or have a specific genetic change (17p deletion). These groups often do not respond well to standard chemotherapy. Part…

This phase 2 trial tests a combination of three drugs—acalabrutinib, lenalidomide, and either rituximab or obinutuzumab—in people with untreated mantle cell lymphoma. The goal is to see how well the combo clears cancer cells from the blood and shrinks tumors. Participants receive…

This study tests a drug called crizotinib in people whose cancer has a specific genetic change called ROS1 translocation. The drug blocks a protein that may help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. Only 4 people took part,…

This phase II trial aimed to test the drug itacitinib in people with severe side effects from cancer immunotherapy that did not get better with steroids. The goal was to see if itacitinib could calm the overactive immune response causing these side effects. However, the study was…

This phase II trial tests the drug afatinib in 40 people with advanced cancers (like solid tumors or lymphoma) that have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer growth. The study aims to see if the …

This study looks at how well the drug tazemetostat works in adults with a slow-growing blood cancer called follicular lymphoma that has returned or not responded after at least two prior treatments. Participants take tazemetostat as prescribed by their doctor in normal medical pr…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This phase 2 trial tests a combination of two drugs, tislelizumab and pemetrexed, in 28 adults with a rare type of brain lymphoma (primary DLBCL of the CNS) that has relapsed or not responded to standard treatment. The goal is to see if the combination can shrink tumors and impro…

This early study tests a new gene therapy called INT2104 in 10 adults with B-cell cancers that have come back or not responded to treatment. The therapy is given as a single IV infusion and works by instructing the body to create its own cancer-fighting T cells and natural killer…

This early-phase trial tests a personalized cell therapy for adults aged 60 and older with B-cell acute lymphoblastic leukemia (ALL) who are in first remission. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack leukemia cells, and infus…

This phase 3 study compares a new oral drug called pirtobrutinib (LOXO-305) against two standard treatment combinations (idelalisib plus rituximab or bendamustine plus rituximab) in 238 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already been t…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and …

This observational study follows 151 Italian adults with chronic lymphocytic leukemia (CLL) who started taking acalabrutinib between May 2021 and April 2022. Researchers want to see how long patients continue the drug and why they might stop, providing real-world insights beyond …

This phase 2 trial tests a combination of two drugs—TTI-622 and pembrolizumab (Keytruda)—in about 10 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune syst…

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study tests whether the drug AG-120 can safely slow or stop the growth of a rare bone cancer called chondrosarcoma that has a specific IDH1 gene mutation. Six adults with advanced or recurrent grade 2 or 3 chondrosarcoma will receive the drug. The main goal is to see how lon…

This study looks at whether a very low dose of radiation (4 Gy) can effectively control a rare, slow-growing type of skin lymphoma called primary indolent cutaneous B-cell lymphoma. Researchers will review records from 52 patients who received this low-dose treatment to see how l…

This study looks at two different approaches to help community hospitals start treating opioid use disorder in patients. One approach is basic training and education, while the other adds extra support like practice facilitation. The goal is to see which method works better at ge…

This early-phase trial tests a new type of CAR T-cell therapy for adults with B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better target and kill cancer cells. The study aims to find the safest dose a…

This study tests whether a daily 10 mg pill called Xanamem can safely slow memory and function loss in people with mild or moderate Alzheimer's dementia. About 247 participants will receive either Xanamem or a placebo for 36 weeks, with an option to continue the drug for up to 10…

This phase 2 trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on lymphoma cells, aiming to prevent the cancer from escaping treatment. It involves 100 adults with relapsed or refractory large B-cell lymphoma who have not responded to standard…

This phase 3 trial tests whether adding brentuximab vedotin to two standard drugs (lenalidomide and rituximab) helps people with diffuse large B-cell lymphoma that has returned or not improved after at least two prior treatments. About 239 participants will receive either the add…

This early-stage study tests a new drug, BGB-11417, in 64 adults with B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for signs that the drug shrinks …

This early-stage trial tests two new drug combinations for people with untreated mantle cell lymphoma, a rare blood cancer. One group gets acalabrutinib plus standard chemo and an antibody; the other gets acalabrutinib plus a targeted pill and the same antibody. The main goal is …

This early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…

This early-phase trial tests two oral drugs—acalabrutinib and ceralasertib—in 12 people with high-risk chronic lymphocytic leukemia (CLL) that has stopped responding to other treatments. The main goal is to check safety and find the right dose. It is not yet known if the combinat…

This study tests a combination of two drugs, copanlisib and venetoclax, in adults with mantle cell lymphoma that has returned or stopped responding to treatment. The goal is to find the safest dose and see how well the drugs shrink tumors. Eight participants are enrolled in this …

This phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…

This study tests a drug called acalabrutinib in Chinese adults with certain blood cancers (mantle cell lymphoma, chronic lymphocytic leukemia, or other B-cell cancers) that have come back or not responded to treatment. The trial has two parts: the first checks safety and how the …

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to fin…

This study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…

This phase 3 trial tests whether a personalized cell therapy called tisagenlecleucel (CAR-T) works better than standard treatments for adults with follicular lymphoma that has come back or stopped responding. About 109 participants will receive either the CAR-T infusion or standa…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This trial was designed to test whether a new radioactive imaging agent, 111In-ABD147, could help detect metastatic solid tumors using SPECT/CT scans. It targeted cancers like castration-resistant prostate cancer and high-grade neuroendocrine tumors. However, the study was withdr…

This study tests an 8-week online stress management program for health students in Sfax, Tunisia. The program combines cognitive-behavioral therapy and mindfulness meditation through videos, exercises, and motivational messages. Researchers will measure changes in stress, anxiety…

This study tests whether an injection made from human fat cells (Tience®) can safely reduce moderate to severe acne scars. Twenty adults aged 18-40 with scars on their cheeks will receive three treatments on one side of the face over three months. Doctors and participants will tr…

This pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…

This study tests a digital program called MINDSET designed to help newly diagnosed cancer patients cope better with treatment. 440 participants will use either the program or a control, and complete questionnaires and blood tests. The goal is to see if the program improves physic…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. About 440 participants will receive either chemotherapy alone or chemotherapy plus levocar…

This study explores whether individualized transcranial magnetic stimulation (TMS) can improve symptoms in adults with irritable bowel syndrome (IBS). Participants receive 10 TMS sessions over two weeks, with brain scans and stool tests before and after to understand how the trea…

This phase 2 trial tests whether combining cognitive behavioral therapy, a stimulant (methylphenidate), melatonin, and light therapy can improve sleep in cancer patients. About 68 patients currently on cancer treatment who have sleep problems will participate. The study measures …

This study looks at whether playing pickleball for 12 weeks can improve thinking skills like attention and memory, as well as motor skills like balance and strength, in adolescents aged 14-18 with mild intellectual disability. Thirty-two students will either play pickleball three…

This study tests whether teaching progressive muscle relaxation and providing psychoeducation can lower stress and increase hope in adults with blood cancers like leukemia or lymphoma. About 75 participants will learn these techniques and report their stress and hope levels. The …

This study tests whether a virtual reality (VR) program can help people undergoing bone marrow transplants cope with stress and improve their quality of life. About 80 adult patients with blood cancer will be randomly assigned to either receive the VR program plus usual care, or …

This study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…

This study tests a text-message counseling program designed to help young adults ages 18 to 25 reduce or stop their cannabis use. Participants must use cannabis at least three days a week and live in Tennessee or Colorado. The program uses peer support and counseling delivered vi…

This study tests whether a structured exercise program can reduce chemotherapy-induced peripheral neuropathy (CIPN) — nerve damage causing pain, numbness, or tingling. About 133 cancer patients who received certain chemotherapies will either follow an exercise plan or receive sta…

This study tests whether a brief behavioral therapy (BBT-CI) or a healthy eating education program (HEAL) works better for reducing insomnia in cancer patients. About 400 adults with stage I-IV cancer who are currently receiving treatment and have sleep problems will take part. T…

This study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study looks at the cost-effectiveness of three treatments for chronic lymphocytic leukemia (CLL) in patients aged 65 and older. Researchers compared ibrutinib alone or with rituximab against bendamustine plus rituximab, measuring both healthcare costs and quality of life. Th…

This study looks at how spirituality — personal beliefs, values, and meaning — influences adults recently diagnosed with blood cancers like lymphoma or leukemia, as well as their loved ones. Participants fill out three questionnaires about spiritual well-being, quality of life, a…

This study looks back at medical records of 500 adults with aggressive B-cell lymphoma that has a MYC gene change. Researchers want to see if a stronger chemotherapy plan called CARMEN leads to better survival and remission rates compared to other treatments. Since it's a review …

This study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…

This study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …

This pilot study aimed to see if it is possible to use neuropsychological tests to measure thinking, memory, and emotional health in adults who received CAR-T therapy for aggressive lymphoma at least six months earlier. The study was withdrawn before enrolling any participants, s…

This study collects blood and bone marrow samples from up to 550 people with blood cancers like leukemia, lymphoma, and myelodysplastic syndrome. Researchers will study the cells, genes, and proteins in these samples to better understand how these cancers develop and to find new …

This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) in real-life settings in Romania. Researchers will collect data from 250 patients over three years to see how long they stay on the drug, why they stop, and how effective …

This study is looking at whether a blood test that measures cell-free DNA (cfDNA) can help doctors know how well first-line treatment is working in people with follicular lymphoma. Researchers will collect blood samples before, during, and after standard treatment, and compare cf…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study does not provide any new treatment. It follows about 1,000 adults who previously received CAR T-cell gene therapy at the NIH. Researchers will check for long-term side effects through blood tests, clinic visits, and annual phone calls for up to 15 years, as required by…

This study tests a symptom questionnaire designed for teenagers with cancer. Researchers will interview 41 adolescents aged 13-17 to see if the survey accurately captures their symptoms. The goal is to improve how doctors understand and manage symptoms in young cancer patients.

This study looks at how cancer and its treatment impact social and emotional development in children aged 4 to 6. About 119 children with brain or solid tumors will complete questionnaires and tasks to measure social skills, thinking abilities, and play behavior. The goal is to u…

This long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…

This study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…

This study uses bone marrow samples from 70 people with blood cancers to create 3D organoids—tiny lab-grown models that mimic the tumor's environment. Researchers will test different chemotherapy combinations on these organoids to see which kills the most cancer cells. The goal i…

This observational study at Mayo Clinic looks at how immunotherapy drugs affect balance and hearing in cancer patients. Researchers will test 50 adults before and during treatment to see if their vestibular (balance) system changes over a year. The goal is to better understand si…

This pilot study aimed to see if giving a logbook to patients hospitalized for a stem cell transplant could help reduce feelings of isolation and psychological stress. The study was withdrawn before enrolling any participants, so no results are available. It was planned at the Un…

This study follows 18 people who previously received GF-CART01, a CAR T-cell therapy for certain blood cancers like lymphoma. Researchers will track side effects and how long the modified cells last in the body for up to 15 years. The goal is to ensure the treatment remains safe …

This study planned to check how often the adrenal glands stop working properly after chemotherapy in adults with blood cancers. It aimed to measure cortisol levels after a stimulation test. However, the study was withdrawn before any participants were enrolled, so no results are …

This observational study follows 321 Italian patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax-based regimens outside of clinical trials. The goal is to describe their clinical features and outcomes, such as how long they live…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at how doctors and patients feel about a new approach to picking antibiotics for people with blood cancers who have a reported penicillin allergy. The goal is to understand what might make it easier or harder to use this approach in everyday hospital care. About …

This study looks at the biology of B-cell lymphoma in children and teens to better understand the disease and long-term effects of treatment. About 128 participants will provide tumor and blood samples for genetic analysis. The goal is not to test a new drug, but to gather knowle…

This study looks at why people with HIV and certain cancers caused by KSHV (Kaposi sarcoma herpesvirus) may lose bone density faster. Researchers will review past CT scans and health records from 40 adults treated at the NIH between 2005 and 2020. The goal is to find factors link…

This study aimed to compare a virtual voice agent with a human agent for teaching cancer patients how to use remote monitoring devices at home. Patients with lung cancer would have been randomly assigned to get instructions from either the virtual agent or a human over the phone.…

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) when used in regular hospitals, not just in clinical trials. Researchers will track 350 patients in France for about 3 years to see how long they stay on the drug and why …

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…

This study looks at how well nutritional assessments can detect malnutrition in older adults with cancer. Researchers will follow 180 patients to see if nutrition status is linked to survival at 6 months and 1 year. The goal is to find better ways to identify and address malnutri…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study looks at whether cancer patients feel their doctors show more empathy during in-person visits with protective gear (PPE) or during video calls without it. About 107 adults from MD Anderson's emergency center will share their views after a conversation with their doctor…

This study is looking for a better way to predict infection risk in people with chronic lymphocytic leukemia (CLL) or multiple myeloma. Researchers will use advanced lab tests on blood samples from 150 participants to find a biomarker that could warn doctors ahead of time. The go…

This study explores whether smartphone sensors can detect early changes in behavior that might signal cognitive decline. About 100 adults aged 65 and older living in assisted living facilities will have an app on their phones that tracks movement, typing patterns, and app usage f…

This study follows 549 children, teens, and young adults with cancer to see how their immune systems respond to COVID-19 vaccines. Researchers collect blood samples to measure protective antibodies. The goal is to learn how cancer and its treatment affect vaccine effectiveness, a…

This study aims to find out how often cannabis withdrawal happens and how severe it is in patients with blood cancers who are hospitalized for a bone marrow transplant or CAR-T therapy. Researchers will track symptoms like mood changes and physical discomfort using a standard que…

This early-phase trial is testing whether ketoconazole, a drug normally used for fungal infections, can get into brain tumors (gliomas) in enough amounts to possibly slow their growth. About 80 adults with different grades of glioma will take low doses of the drug before their sc…

This study is not testing a new drug or treatment. Instead, it will observe how doctors in Russia currently treat chronic lymphocytic leukemia (CLL) in everyday practice. About 6000 adults with CLL will be followed for up to 2 years to collect information on their health, treatme…

This study tests a new way to choose treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to standard therapy. Researchers use a lab test that checks many drugs at once, along with genetic information, to find which drug or d…

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This study follows 500 children and young adults who received gene therapy for cancer as part of earlier trials. Researchers will monitor them for up to 15 years to detect any delayed side effects. Participants have blood tests and health check-ups at regular intervals. No new tr…

This study looks at whether a self-administered geriatric assessment can help predict serious side effects in people aged 60 and older with Non-Hodgkin lymphoma who are starting chemotherapy. The goal is to see if this assessment can identify who is at higher risk for hospitaliza…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study follows 50 young men who had cancer or blood disorders as children and received treatments that can harm fertility. Some stored testicular tissue before treatment; others did not. Researchers will check their fertility through exams, ultrasounds, blood tests, and semen…

This study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related disorders. The samples are stored in a tissue bank for future research to understand what causes these cancers, how they pr…

This study surveys parents of children with cancer to learn about their attitudes and beliefs regarding the risks of using opioids for pain. Pain is common in pediatric cancer, and opioids are a key treatment, but parents often hesitate or underuse them. The goal is to fill a kno…

This study analyzes tumor and blood samples from 763 people with bone cancer (osteosarcoma) to understand why some tumors resist chemotherapy. Researchers will test how cancer cells respond to drugs in the lab and look for genetic clues. The goal is to learn more about treatment …

This study watches how people with chronic lymphocytic leukemia (CLL) feel and function while taking standard oral treatments. About 146 adults in Spain will fill out questionnaires about their symptoms, fatigue, and worries during routine doctor visits. No new drugs are given—th…

This study tests whether adding automatic reminders to echocardiogram (heart ultrasound) reports can increase the number of patients with heart valve disease who see a cardiologist within six months. Researchers will randomly assign 300 patients' reports to receive no prompt, a p…

This study looks at how the COVID-19 pandemic impacted the quality of life of 274 cancer patients who also have neuropathy (nerve pain). All participants had taken part in earlier clinical trials. Researchers want to see if there are differences between those who received a brain…

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…